Dr. Patterson "gospel" for today:
A very interesting detailed explanation in the Beckman Coulter conference with much more "meat". As must see (data not published in his paper included).
https://www.beckman.com/resources/videos/symp...1591885071
Quote:RANTES signals the transition from virologic to immunological predominance that is very clear from the data we have in hand from over hundreds of patients that are enrolled in the mald-to-moderate trial and the severe trial and the emergency use IND patients that are severe and critical in the hospital, some of those patients were on life support and were given Leronlimab came off ECMO and where ex-tubated and now are either home or in rehab hospitals trying to get their strength back.
And what I have said in numerous interviews is you know that the comments that we get about this is been anecdotal evidence you have to do you know placebo controlled blinded studies, which we are doing, we’re going through the proper channels to take a look at that, but my response being a pathologist and a virologist for over 25 years is: anecdotes don't come off life support, and I think, you know we know it we have to do to prove with you know to convince the community at large, were doing it, but with over 25 years’ experience sometimes you just know when something is working.
The response to the humanized anti CCL5 humanized antibody Leronlimab is dramatic in the severe critical disease and, like I said, early indications suggest a similar response in mild moderate patients , a double blind placebo controlled trails are under way to confirm the mechanism of action and it’salignment with the outcome; that’s the thing that’s been missing with some of the therapeutic approaches in COVID right now, is a disconnect between the mechanism of action and the outcome, and we're seeing that with antivirals that don’t decrease, you know, the viral load , and we're seeing that with piece-meal approach is to inhibit, you know, one molecule of a cytokine storm or another. What is it going to do to the immune system in general in, you know, potentially preventing other superinfections by bacteria and other viruses in and what is what is decreasing the cytokine storm going do for the coagulopathies and the renal failure’s and the liver enzyme elevations.
The fact is, a third of all patients who are hospitalized have some degree of renal failure , so again, there is another hurdle to the majority of the drugs that are out there that have renal issues or liver issues in and can’t be used in in these patients who, who get sick very quickly, and have significant morbidity, and like I said, Leronlimab are being investigated for the other indication such as cancer and HIV, like I said by looking at the immunology of COVID we have learned a lot about this drug, we’ve learned a lot about the fact that this drug when bound to CCR5 initiates a number of cellular-based activities that certainly IncellRx who has made a life out of looking at individual cells and cell-based activities is really investigating to a great extent it’s exciting to see something work like this beyond just, just blocking a chemokine receptor.
A very interesting detailed explanation in the Beckman Coulter conference with much more "meat". As must see (data not published in his paper included).
https://www.beckman.com/resources/videos/symp...1591885071
6
